Skip to main
ALLR
ALLR logo

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc. presents an attractive valuation characterized by a notable increase in its price target to $9.25, indicating substantial upside potential. The company’s lead candidate, stenoparib, has demonstrated significant clinical benefits for patients suffering from advanced recurrent ovarian cancer, addressing a critical unmet medical need. Furthermore, the strategic use of proprietary Drug Response Predictor technology enhances patient selection and clinical outcomes, potentially positioning the company favorably within the oncology market.

Bears say

Allarity Therapeutics Inc reported a net loss of $2.37 million, resulting in an earnings per share (EPS) of $(0.15), which was an improvement compared to earlier estimates of $(0.21) but still indicates ongoing financial challenges. The company faces several significant risks, including balance sheet and liquidity issues, potential failure of its product candidates to prove safety and efficacy in clinical trials, and obstacles related to regulatory approvals and commercialization. Additionally, external factors such as competition, changes in healthcare priorities, and investor sentiment toward the biotech sector contribute to a negative outlook for the company's stock.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.